Company profile
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer,
- CEO
- —
- Headquarters
- Philadelphia, PA, United States
- Employees
- 46
- IPO date
- Feb 6, 2014
- Sector
- Healthcare
- Industry
- Biotechnology